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Abstract
Objectives Populations are aging worldwide. This paper summarizes some of the challenges and opportunities due to the 
increasing burden of infectious diseases in an aging population.
Results Older adults typically suffer elevated morbidity from infectious disease, leading to increased demand for healthcare 
resources and higher healthcare costs. Preventive medicine, including vaccination can potentially play a major role in preserv-
ing the health and independence of older adults. However, this potential of widespread vaccination is rarely realized. Here, 
we give a brief overview of the problem, discuss concrete obstacles and the potential for expanded vaccination programs to 
promote healthy aging.
Conclusion The increasing healthcare burden of infectious diseases expected in aging populations could, to a large extent, 
be reduced by achieving higher vaccination coverage among older adults. Vaccination can thus contribute to healthy aging, 
alongside healthy diet and physical exercise. The available evidence indicates that dedicated programs can achieve substantial 
improvements in vaccination coverage among older adults, but more research is required to assess the generalizability of the 
results achieved by specific interventions (see Additional file 1).
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Introduction
Worldwide, populations are aging due to ever increasing life 
expectancy and decreasing birth rates. The United Nations 
estimates that 15% of the world’s population will be over the 
age of 60 years by 2025 and that this proportion will rise to 
well over 20% by 2050 [1]. In Europe as well as Japan, the 
proportion of people aged 65 years or older will double from 
2010 to 2060 and the proportion of people aged 65 years or 
older relative to the population of working age (15–64 years) 
is expected to double by 2060.
This demographic development is already starting to 
put considerable strain on public finances in countries with 
state-financed pensions and healthcare systems and the 
effects can only be expected to increase [2, 3]. Without sub-
stantial (and politically difficult) changes in policy, the tax 
base will diminish because of the fall in the proportion of 
working age (and tax-paying) adults while pension expenses 
will grow, both because of continued increases in life expec-
tancy and the sheer growth in the number of people eligi-
ble for pensions. Furthermore, it is expected that healthcare 
expenditures will increase substantially, as individual need 
for healthcare services rises markedly with advancing age.
Only recently have the implications and the dimensions of 
the coming problems been more widely recognized, leading 
to various strategies being debated. These various measures 
are aimed at keeping older adults economically and socially 
active longer than has been common in prior generations on 
the one hand—the concept of “adding life to years”—and 
on the other to delay as much as possible the inevitable age-
related increase in healthcare utilization—a concept desig-
nated as “healthy aging” [4].
Discussion
Healthy aging
The World Health Organization has recently defined the 
concept of healthy aging as “the process of developing and 
maintaining the functional ability that enables well-being in 
older age” [4]. Healthy aging is obviously a laudable objec-
tive on its own to improve welfare and quality of life (QoL), 
but it is also specifically recognized as necessary to counter 
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Fig. 1  Healthy vs premature aging. Typically, aging is associated 
with a decline in physical capability, during adulthood, from being 
fit and physically active to being well (that is, without obvious physi-
cal incapacity, but with reduced physical activity). In most adults, 
the later phases of life are characterized by frailty and disability. 
Disability is simply enough defined as the inability to perform basic 
day-to-day functions without assistance. Frailty is more difficult to 
define, but is often identified as meeting 3 or more of the following 
clinical criteria: a low level of physical activity, exhaustion or low 
energy, muscle weakness, slowness, and unintentional weight loss. 
The underlying etiology of frailty is poorly understood, but includes 
comorbidities such as diabetes, obesity and respiratory illnesses. 
Immune dysfunction also seems to be a key factor in two ways. First, 
through chronic inflammation, mitochondrial dysfunction and cellular 
senescence that may degrade the endocrine, hematologic and muscu-
loskeletal systems, and secondly, by increasing susceptibility to infec-
tions, which can further harm these physiologic systems. The ideal of 
healthy aging (living with as little time spent in frailty or disability) is 
contrasted to rapid aging in this simple schematic. In reality, however, 
aging for most people is a nonlinear process. Acute incidents such as 
physical trauma from falls, social stressors such as divorce or death of 
a spouse, or acute illness (for example, from cardiac disease or infec-
tion) can trigger sudden losses of capacity, which in older individuals, 
become increasingly difficult to recover from. This places a priority 
on intervention to prevent those acute incidents to prevent frailty/dis-
ability and maintain quality of life
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Traditional stereotypes are no longer applicable to the 
current population of older adults, who are often healthier 
and more active than prior generations and the focus today is 
not on chronological age but on functional ability and inde-
pendence [4]. In particular, there is consensus that we need 
to delay the onset of “frailty”, a common clinical syndrome 
in older adults that carries an increased risk for poor health 
outcomes including disability, hospitalization and mortality 
[5, 6] (Fig. 1). Development of frailty is often associated 
with a decreased ability to respond to immune stimuli, so-
called immunosenescence (see Text Box 1). Lower immune 
responses in older adults correlate with higher susceptibility 
to infectious diseases and a higher risk of hospitalization or 
serious outcomes than in a younger person, further compli-
cated by the higher prevalence of comorbidities common in 
older adults [7].
For example, infections of the lower respiratory tract are 
now the fourth most frequent cause of death in developed 
countries, with approximately 75% of cases occurring in 
adults aged 60 years and older [8, 9]. As another example, 
in the United States it is estimated that 40,000–80,000 peo-
ple die annually from vaccine-preventable diseases (VPDs), 
while hundreds of thousands more are hospitalized [1, 10]. 
The majority of cases and 99% of the deaths from VPDs 
are in older adults [11]. Given these numbers and existing 
trends in disease incidence, infectious diseases represent a 
major barrier to healthy aging and the burden of infectious 
diseases in adults over age 60 years is coming to represent 
a significant and increasing proportion of healthcare expen-
ditures [12].
dysregulation and chronic inflammation have been sug-
gested as primary drivers of frailty [15]. Consistent with 
this, biomarkers typically associated with increased 
inflammation appear to be predictive of frailty, mortality 
and elevated disease risk [16, 17]. Since frailty appears 
to be a better predictor of disability, institutionalization 
and mortality than chronological age, the implications for 
both healthcare costs and personal QoL, if we can under-
stand how to delay the onset of frailty, are enormous.
The elevated risk of infection and disease in older 
adults, and especially in the frail elderly, correlates with 
a decreased ability to respond to vaccination. It is also 
associated with a decreased pool of naive T cells, a rela-
tive increase in the proportion of memory T cells and 
an increased proportion of CD8+ T cells [18]. While it 
reaches pathological levels in the frail elderly, immunose-
nescence can be viewed as the culmination of a process 
that develops throughout life, in response to continuous 
immunological stimulation: in some cases, decreased 
immune responses to vaccination can be seen even in 
young adults compared to children [19, 20].
Text box 1. Immunological frailty
Frailty is a syndrome that covers the functional ability of 
an individual in both mental and physical spheres, and 
increasing frailty is associated with decreased capacity in 
these areas and an increased risk of mortality. Frailty can 
be viewed as either an accumulation of comorbidities, or 
as a loss of the ability to respond effectively to environ-
mental stressors [13, 14]. Regardless of definition, there 
is consensus that increasing frailty is associated with an 
increased risk for further physiological decline, suggest-
ing a causal linkage [13].
While aging is clearly linked to frailty, both terms are 
not synonymous. Some individuals become clinically 
frail by the age of 70 years, while in others this may 
not happen until 90 years of age [14]. Frailty also seems 
to be tightly linked to loss of immunocompetence and 
greater susceptibility to infection (a combination referred 
to as immunosenescence), to the extent that immune 
Vaccination—a tool for healthy aging
Increasing vaccination coverage of older adults against 
VPDs can be expected to promote healthy aging. The VPDs 
particularly relevant for older adults currently include sea-
sonal influenza, invasive pneumococcal diseases, pneu-
monia, herpes zoster (shingles), meningococcal diseases, 
pertussis, diphtheria, tetanus and hepatitis [21]. Numerous 
studies have been carried out to assess vaccination of older 
adults against these VPDs in terms of avoided cases and 
savings in healthcare resources and costs (e.g., [10, 22–24]). 
As just one example, a Europe-wide study showed that vac-
cination coverage of 75% of adults over 65 against seasonal 
influenza could result in 1.6–2.1 million cases prevented, 
25,000–37,000 influenza-related deaths avoided and savings 
of healthcare costs amounting to €153–219 million annually 
[22]. This is probably only the tip of the iceberg as there is 
substantial additional morbidity associated with infectious 
diseases in terms of serious sequelae (see Text Box 2). Even 
when vaccination is not 100% effective in preventing infec-
tion with a pathogen, it may still attenuate the course and 
severity of a disease [25, 26].
Despite the availability of effective and well-tolerated 
vaccines against these diseases, many countries struggle to 
reach recommended coverage levels even when vaccination 
is supported by national programs. The reasons include lack 
of knowledge, poor infrastructure for adult vaccination or 
perceptions that the benefits of vaccination of older adults 
may not justify the costs (see Text Box 3).
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Text box 2. The hidden costs of infectious disease 
in older adults
Cost‐effectiveness analyses of vaccination typically focus 
on the morbidity and mortality directly attributable to a 
specific pathogen and the percentage of this burden of 
disease that can be prevented by a vaccination program. 
However, in older adults, particularly those of advanced 
age, comorbidities such as cardiovascular disease, type‐2 
diabetes, chronic obstructive pulmonary disease and renal 
or hepatic dysfunction are common, and these can be 
negatively impacted by infectious diseases [27]. In addi-
tion, the course of disease in older adults is typically 
more severe, the period of recovery more prolonged, and 
the risk of complications higher. As one example, herpes 
zoster (HZ) in younger adults is uncommon, typically 
transient and usually resolves without serious complica-
tions. In older individuals however, not only does the 
incidence of HZ increase significantly but so does the 
risk of complications such as postherpetic neuralgia, 
which in some cases can cause chronic, debilitating pain 
lasting for months or even years [28]. Older HZ patients 
also have an excess risk of stroke amounting to 30% in 
the year after HZ onset [29]. Combined, these factors 
represent a significant risk to the patient’s QoL and their 
ability to continue working or living independently [30].
Similar data are available for other VPDs. One study 
of 36,636 outpatients aged ≥ 65 years with a chronic 
illness indicated that vaccination against influenza and 
pneumococcus reduced the risk of ischemic stroke and 
acute myocardial infarction by approximately a third. 
Compared with unvaccinated individuals, the vacci-
nated persons had a substantially reduced risk of death 
and reduced risk of coronary and intensive care admis-
sions in the year following vaccination [31]. Indeed, the 
commonest causes of severe disability in older adults 
including strokes, congestive heart failure, pneumonia, 
ischemic heart disease, cancer, and hip fracture, have 
all been linked to influenza [18]. In the US, 90% of the 
estimated 30–40,000 deaths linked to influenza occur in 
older adults and are related to cardiovascular and pulmo-
nary complications [32].
The costs resulting from loss of employment, loss of 
independence and need for rehabilitation or inpatient care 
due to chronic disease arising subsequent to infection can 
be substantial. These risks can potentially be significantly 
reduced by vaccination, but are typically not considered 
in analyses of vaccine cost‐effectiveness [33].
Text box 3. Challenges for vaccination in older 
adults
The most immediate challenge to vaccination in older 
adults is the decreased immune response associated with 
aging. This is characterized not just by decreased spe-
cific antibody titers generated by vaccination, but also 
by a more rapid decline in titers, suggesting rapid loss of 
immune memory [34]. The mechanisms involved are not 
yet fully defined, but do not appear to involve the loss of 
immune cells capable of recognizing the response [35]. 
Instead, it may reflect a change in the balance of existing 
immune memory and a relative decline in the proportion 
and types of memory T cells [36, 37]. If correct, this 
could explain the difficulty of generating durable mem-
ory responses with vaccines containing higher doses of 
antigen. This may simply boost an existing population 
of differentiated antigen‐specific cells which are already 
dysfunctional with regard to immune memory [36]. How-
ever, the observation that adjuvanted vaccines can gener-
ate stronger immune responses that apparently persist for 
longer periods of time, even in individuals aged 70–90 
years, suggests that, given the correct stimuli, functional 
memory responses can be generated de novo from the 
existing pool of T cells [38–41].
Improved vaccine efficacy has consequences beyond 
those expected from a reduction in disease incidence 
in vaccinated individuals. No vaccine is effective if not 
used, and vaccination in older adults has been hampered 
by concerns among some older adults, vaccinators and 
public health officials that it is ineffective or too short‐
lived to be worth pursuing—in other words that the ben-
efit/risk ratio is low [42]. Vaccines that can demonstrate 
enhanced efficacy and durable protection in older adults 
may therefore be key to persuading the population to 
request them and public health systems to deliver them.
Immunosenescence
Human aging is characterized by a chronic, low-grade 
inflammation, a phenomenon termed “inflammaging”, which 
is a highly significant risk factor for morbidity, frailty and 
mortality in older adults as most, if not all, age-related dis-
eases share an inflammatory pathogenesis [43]. This low-
grade inflammation not only accelerates tissue degeneration 
and wasting, but also influences adaptive immune responses 
which are at the core of generation of immune memory and, 
therefore, immunization.
Activation of the innate immune system resulting in 
the production of cytokines during aging can be caused by 
waning control of latent infections, less effective physical 
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barriers (more permeable skin, defective mucosal barriers 
in gut and respiratory systems) or increase in overall tissue 
damage [44, 45]. In addition, age-associated intrinsic defects 
in innate immune cells as well as accumulation and activa-
tion of non-immune cells such as adipocytes contribute to 
inflammaging.
The initiation of a T-cell response to a vaccine requires 
activation of dendritic cells that present antigenic fragment 
peptides derived from the vaccine to T cells. This process, 
which is the major target for the adjuvants in vaccines, 
appears to be disturbed in an inflammatory environment or 
with older dendritic cells. Understanding of the mechanisms 
of action of adjuvants and vaccine delivery systems and 
identifying those that are more effective in older individu-
als remain an area of active research [46, 47].
The adaptive immune response of T and B cells, the back-
bone of a vaccine response, is also susceptible to aging [34] 
and the previous decade has seen a surge in research on 
how and where this process is impaired in older individu-
als. Defects in adaptive T-cell responses already begin to 
become significant about the age of 50 years, in particular in 
individuals with comorbidities. However, at least for healthy 
individuals, the sizes and repertoires of antigen-specific 
CD4+ T cells and B cells do not appear to be decreased to a 
biologically relevant extent in older adults [35].
Instead, at least part of the problem seems to be the 
reduced ability of antigen-specific lymphocytes to sur-
vive as long-lived memory T cells [36]. It is possible that 
chronic infections such as cytomegalovirus may compromise 
antigen-specific responses and help drive the development 
of immunosenescence [48, 49]. Whether this defect can be 
overcome by better vaccines or adjuvants or requires phar-
macological intervention during the development of T-cell 
responses after vaccination remains uncertain. In contrast 
to CD4+ T cells, CD8+ naive and central memory T cells, 
apparently the weak link in immune aging, are increasingly 
lost and become dysfunctional with age [37]. Depending on 
the infection targeted by vaccination, it might be advanta-
geous to generate an effective CD8+ memory population 
earlier in life, but induction of a CD8+ T-cell response 
generally requires a live vaccine, whereas the inactivated 
or component vaccines previously developed preferentially 
induce CD4+ T-cell and B-cell responses.
The economics of adult vaccination
Alongside investments in infrastructure to improve water 
sanitation, vaccination programs are usually considered as 
the most important factor in improved public health and 
longevity worldwide over the last century. It is increasingly 
recognized that proper assessments of the economic value 
of vaccination needs to take a broader perspective than just 
focusing on the clinical benefits and the avoided healthcare 
costs that may be attributed to prevention of a single, spe-
cific disease. The broader economic benefits to consider 
and attempt to quantify include improved educational 
attainment, productivity gains from ameliorated effects of 
multi-morbidity on general health and cognition, community 
externalities and political stability [50, 51].
Intangible benefits of vaccination considered specifically 
in relation to vaccination of older adults, include attenuated 
severity of disease in breakthrough cases [25] and reduc-
tions in complications and comorbidities. Examples are stud-
ies showing that influenza and pneumococcal vaccinations 
may reduce the incidence of myocardial infarction by up to 
50% [52]. Another example is that herpes zoster is strongly 
associated with an increased risk of stroke, an excess risk 
which may be prevented by effective vaccines [29] (See Text 
Box 2).
Another consideration is that vaccination may diminish 
the problems related to polypharmacy in older adults with 
many comorbidities, which may lead to important adverse 
effects or lack of compliance [52]. Another intangible ben-
efit of vaccination, which is increasingly recognized (and not 
limited to vaccination of older adults), is that it may reduce 
the use of antibiotics [53–55] and thus diminish the growing 
problems caused by the development of antibiotic-resistant 
strains of bacteria. The United Kingdom Joint Committee on 
Vaccination and Immunization has recently recommended 
that this effect be included in economic evaluations of new 
vaccines and vaccination programs [56].
The most widely used approach to economic evaluation 
of healthcare interventions (including vaccines) is cost-
effectiveness or cost-utility analyses, which aim to assess the 
incremental benefits of the intervention relative to its incre-
mental costs, usually taking the perspective of the healthcare 
system in estimating the costs. This type of economic assess-
ment is used in many countries by healthcare authorities for 
making decisions about reimbursement of new treatments. 
For preventive interventions like vaccines, the assessments 
usually seek to estimate the loss of utility (QoL) avoided 
by the intervention and relate this to the incremental costs 
incurred relative to no intervention. The result is expressed 
as the incremental costs per quality-adjusted life-year 
(QALY) gained (or, more accurately, not lost), which may 
then be compared to a benchmark to determine whether the 
intervention is cost-effective or not. Commonly used bench-
marks in Europe range from 20,000 to 30,000 €/QALY, but 
few countries have set an explicit, official limit.
A number of economic evaluations and reviews of vac-
cination of older adults have recently been published, for 
example of pneumococcal conjugate vaccines [57] and her-
pes zoster vaccine [58, 59]. Generally, these evaluations con-
clude that vaccination is cost-effective but even taking the 
narrow direct cost perspective there are important challenges 
to meet when making such assessments. Among these are 
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heterogeneity between targeted older individuals in terms 
of risk of infection, response to vaccination and severity of 
disease, just as there may be age-related variations in dura-
tion and level of immunity induced by vaccination [60].
It is also of interest to note that, ignoring the difficult 
assessment and valuation of health outcomes, studies of 
the costs of interventions show that the costs of vaccination 
are lower than those of many other preventive interventions 
and the potential benefits substantial (see Text Box 4). A 
recent study estimated that the total costs of fully adhering 
to recommended vaccinations over the full course of life in 
several European countries was much lower than those of 
many widely used preventive measures such as taking statins 
to prevent cardiovascular complications [61].
[65] and the government is proposing a Healthy Aging 
program, which is projected to save 5 trillion yen (approx. 
40 billion Euros at current exchange rates) by 2025, with 
almost a fifth of that coming from reduction in VPDs 
(primarily pneumonia) [65]. Other nations estimate 
potential savings of a similar magnitude. For example a 
recent study estimated that under-vaccination of adults 
costs the US 7.1 billion USD in healthcare expenditure 
per year [12].
Text box 4. Vaccination programs for healthy 
aging
The proportion of the population over 65—and especially 
over 85—years of age has increased dramatically over the 
last half century and this trend is only expected to accel-
erate. While the decrease in mortality is to be celebrated, 
there is concern over the implication that a declining ratio 
of those in employment to those no longer working will 
place stress on government budgets, and that the greater 
risk of illness in older individuals will place particular 
stress on public health budgets [62]. Some steps have 
already been taken to address the first of these concerns, 
as seen in the many countries raising the qualifying age 
for retirement and pension eligibility. However, for such 
policies to be successful, older individuals must remain 
healthy enough to continue working. Additionally, while 
an increased demand for healthcare is unlikely to be 
entirely avoidable in an aging population, there is grow-
ing focus on ways of diminishing the burden of disease in 
older people, a concept generally called “Healthy aging”.
A key component of healthy aging strategies is the 
recognition that infectious disease is likely to play an 
increasing role in morbidity among older individuals 
([63] and Text Box 2) and that vaccination is among the 
most cost‐effective interventions. Consequently, we have 
seen expansion of vaccination programs and recommen-
dations shifting from a predominantly pediatric focus to 
one covering the whole lifespan, so‐called life course 
immunization, [64] as well as the development of vac-
cines specifically targeting diseases in older adults (see 
Text Box 3). The scale of the challenge—and the poten-
tial benefits—are dramatic. In Japan, the currently most 
advanced country in the demographic transition, control 
of infectious diseases and vaccination are among the 
Ministry of Health, Labour and Welfare’s top priorities 
Adult vaccination: recommendations and coverage
Despite the accumulating evidence of the benefits of vac-
cination of older adults, vaccine uptake is generally lim-
ited and far below targets [60]. To improve this situation, it 
is necessary to identify the barriers to increased uptake of 
vaccinations among older adults and to modify these where 
possible.
Vaccine programs for children and younger adults have 
shown that great declines in the incidence of infectious dis-
eases can be achieved if vaccination is properly implemented 
[25]. In the United States, coverage rates in children for most 
recommended vaccines reach approximately 90% [66]. Euro-
pean countries are more diverse, both in their recommended 
vaccines and the recommended schedules, but the coverage 
for the most common pediatric vaccines (measles, diphthe-
ria, pertussis, tetanus, tuberculosis, polio, etc.) reaches or 
exceeds 90% in most EU countries [67]. These programs 
indicate what is needed for successful disease control by 
vaccination and thus demonstrate the opportunities for adult 
vaccination programs. Comparing current pediatric vacci-
nation programs with what is being done to enhance vacci-
nation of older adults also highlights important differences 
and the challenges that must be overcome to improve adult 
vaccination rates.
Where adult vaccination is recommended, there are wide 
divergences in what is recommended (Table 1) and in the 
coverage levels reached. In a recent survey of immuniza-
tion policies in 31 high-income countries [68], only 12 had 
comprehensive adult vaccination policies, although all of 
them had recommendations for at least one adult vaccination 
(influenza, with programs in place to monitor the vaccination 
coverage in adults in 29 of the countries). In two countries, 
influenza vaccination is recommended for the entire popula-
tion, whereas in the rest it was only recommended for risk 
groups. Despite recommendations and public funding, only 
one country in this study (the Netherlands) exceeded the 
recommended level of coverage (75%) while many reached 
less than 50% [68]. For the other vaccines, recommendations 
are most common (26–27 countries) for adult immunization 
against hepatitis B, pneumococcus, tetanus and diphtheria, 
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Table 1  Recommended vaccinations for adults in selected high-income countries [71–78]
This table compiles recommended, age-specific vaccinations for older adults (from 50 years of age). It does not include catch-up vaccinations for 
vaccines typically given at younger ages, vaccines which are available but not recommended or reimbursed, vaccinations recommended for spe-
Vaccine Recommended vaccination Country
Diphtheria No national recommendation Croatia, Czech Republic, Denmark, Hungary, Iceland, Ireland, Japan, Republic of 
Korea, Malta, Netherlands, Norway, Romania, United Kingdom
Single booster Poland (in adulthood), Spain (at age 65)
Adult, every 10 years Austriaa, Belgium, Bulgaria, Canada, Cyprus, Estonia, Finland, Germany, Greece, 
Italy, Latvia, Luxembourg, Slovenia, United States
65+, every 10 years Franceb,  Lichtensteinb,  Portugalb,  Switzerlandc
Other New Zealand (every 20 years), Slovakia (50+, every 15 years), Sweden (50+, every 
20 years)
Tetanus No national recommendation Denmark, Hungary, Iceland, Ireland, Japan, Republic of Korea, Malta, Netherlands, 
Norway, Romania, United Kingdom
Single booster Croatia (at age 60), Poland (in adulthood), Spain (at age 65)
Adult, every 10 years Austriaa, Belgium, Bulgaria, Canada, Cyprus, Estonia, Finland, Germany, Greece, 
Italy, Latvia, Luxembourg, Slovenia, United States
65+, every 10 years Czech  Republicc,  Franceb, Lichtenstein,  Portugalb,  Switzerlandc
Other Lithuania (every 5–10 years), New Zealand (every 20 years), Slovakia (every 
15 years), Sweden (every 20 years)
Pertussis No national recommendation Bulgaria, Canada, Croatia, Cyprus, Denmark, Estonia, Finland, Hungary, Iceland, 
Ireland, Latvia, Lithuania, Japan, Republic of Korea, Malta, Netherlands, New 
Zealand, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzer-
land, United Kingdom
Single booster in adulthood Belgium, Czech Republic (at age 65), France, Germany, Greece, Slovenia, United 
States
Adult, every 10 years Austriaa, Italy, Luxembourg
65+, every 10 years Lichtensteinb
Shingles (Herpes zoster) No national recommendation Bulgaria, Croatia, Cyprus, Denmark, Estonia, Finland, Germany, Hungary, Iceland, 
Ireland, Japan, Republic of Korea, Latvia, Lithuania, Luxembourg, Malta, New 
Zealand, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, 
Spain, Sweden
Vaccination at 50+ Austria, Czech Republic
Vaccination at 60+ Canada, Greece, United States
Vaccination at 65+ Belgiumd,  Francee, Italy
Vaccination at 70+ Australia, United Kingdom
Influenza (Trivalent) No national recommendation Swedenf
Annual vaccination at 60+ Germanyf,  Greecef, Hungary, Iceland, Netherlands, Slovakia
Annual vaccination at 65+ Australia,  Belgiumf,  Bulgariaf, Canada, Croatia, Cyprus, Denmark,  Estoniaf, 
 Finlandf,  Francef,  Irelandf,  Italyf, Japan, Republic of Korea,  Latviaf,  Lithuaniaf, 
Luxembourg, New Zealand,  Norwayf, Portugal,  Romaniaf,  Spainf,  Switzerlandf, 
United  Kingdomf
All adults Austriaf, Czech  Republicf,  Maltaf,  Polandf,  Sloveniaf, United  Statesf
Pneumonia (S. pneumoniae) No national recommendation Bulgaria, Croatia, Estonia, France, Latvia, Lichtenstein, Lithuania, Netherlands, 
New Zealand, Portugal, Romania,  Switzerlandh
50+, PPV Hungary
50+, PCV Poland
50+, PCV and  PPVg Austria
60+, PPV Germany, Iceland
60+, PCV Slovakia
60+, PCV and  PPVg Luxembourg
65+, PPV Australia, Canada, Cyprus, Ireland, Japan, Republic of Korea, Norway, Spain, 
Sweden, United Kingdom
65+, PCV Greece, Malta
65+, PCV and  PPVg Belgium, Czech Republic, Italy, United States
65+, PCV or PPV Denmark, Finland, Slovenia
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although again, these recommendations primarily focus 
on risk groups and travelers [68] and coverage is generally 
poor [69]. Overall, the picture of adult vaccination is one of 
fragmented recommendations, restricted coverage [70], and 
significant data gaps [68].
Adult vaccination: building effective programs
To understand why adult vaccination coverage is low, it is 
useful to examine those countries that have achieved the 
highest coverage and also to compare adult vaccination 
programs with pediatric vaccination programs. Successful 
pediatric vaccination programs generally recommend uni-
versal vaccination, they are supported by effective funding 
mechanisms, and the outcomes are assessed (and the pro-
grams corrected, if needed) based on routine surveillance 
of disease and vaccination coverage.
The important role of recommendations is suggested by 
the observation that countries with comprehensive vaccina-
tion recommendations for older adults tend to include more 
vaccines in their programs [68] and to reach higher levels of 
coverage with the recommended vaccines [67]. In addition, 
there is evidence that vaccination recommendations focusing 
on groups at risk, although apparently offering an efficient 
approach to vaccination, may actually inhibit uptake, since 
they may inadvertently send the message that the national 
health system does not see the recommended vaccines as 
important [79]. However, this evidence must be critically 
assessed in the light of economic evaluations, which often 
conclude that universal vaccination of older adults against a 
particular VPD is not cost-effective and that programs must 
be targeted to specific, well-characterized groups to ensure 
acceptable incremental costs per QALY gained [80].
As all the evidence identifies provider recommendation as 
the principal reason for adults to become vaccinated [1], this 
implies that if few providers are convinced of the importance 
of adult vaccination the uptake will remain low. Numerous 
studies show that many primary-care physicians do not con-
sider vaccination of older adults a high priority [81–85].
Without funding, however, recommendations have lim-
ited effect. While most high-income countries have some 
form of public funding in place for recommended vaccines 
[82], cost can still be a barrier to access and may discour-
age HCPs from recommending the vaccine. As one exam-
ple illustrating this, moving from a partial to a full subsidy 
of pneumococcal vaccination for older adults in Australia 
raised the uptake from 39 to 73% in patients attending a 
large public hospital [86]. Similarly, pediatric vaccination 
in the United States is financially supported by the Vaccines 
for Children initiative and this has virtually eliminated pre-
viously significant regional, ethnic and socioeconomic dis-
parities in vaccination coverage [87]. In contrast, the same 
vaccines for adults can require substantial copayments, and 
ethnic and socioeconomic disparities in coverage rates are 
clearly visible [70].
These findings suggest that four things are necessary to 
support effective vaccination programs, both in children and 
in adults (Fig. 2). First, a clear commitment to vaccination 
must be reflected in a coherent, comprehensive public policy. 
Second, a commitment to fund and deliver vaccines to the 
population is required, whether via predominantly public 
funds as in the United Kingdom and the Netherlands, or a 
mixture of public and private funds as in the United States. 
Third, effective surveillance of vaccination coverage and 
the burden of disease is required, so that goals can be set, 
priorities established, and the effectiveness of the program 
monitored and adjusted, if necessary. Finally, the safety and 
value of vaccination must be understood and appreciated 
both by the target population and by vaccinating healthcare 
professionals.
The first three of these factors can be implemented by 
public policy and the initial steps have already been taken 
in many countries. However, for adult vaccination programs 
to achieve the same kind of success as pediatric programs 
have, they need a similar degree of population acceptance. 
This is particularly an issue for adult vaccination because 
there is a widespread public perception that vaccination is 
not needed [90] and the decision of the individual to seek 
or accept vaccination is crucial. For infant vaccination, the 
cific risk groups or vaccinations recommended in response to specific activities such as travel or transplantation
PCV pneumococcal conjugate vaccine, PPV pneumococcal polysaccharide vaccine
a Every 5 years from age 65
b Every 20 years for younger adults
c Every 10–15 years for younger adults
d Cap at 79 years of age
e Cap at 75 years of age
f Quadrivalent vaccine also available, though prioritization and access varies by region
g Initial dose is the conjugated pneumococcal vaccine, followed by the polysaccharide pneumococcal vaccine
h The use of PPV, with or without PCV, is being re-evaluated
Table 1  (continued)
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messages are targeted at the parents. For adult vaccination, 
the vaccine recipients must be reached with a message that 
can convince them of the value and safety of vaccination 
directly to themselves or to their family. Additionally, it is 
important that vaccinating healthcare personnel understand 
the value of vaccination both for themselves and for patients.
These considerations are supported by interventions that 
have been associated with substantial improvements in adult 
vaccination coverage [88, 89]. Important common elements 
to improve coverage seem to be: clear national objectives 
and commitments; incentives for healthcare personnel to 
vaccinate; vaccination reimbursement systems; informa-
tion and awareness campaigns; clear coverage objectives. 
However, even programs considered as highly successful 
often plateau at a suboptimal level of coverage [89]. These 
plateaus vary between vaccine types thereby indicating that 
vaccine-specific issues must be addressed as well.
Conclusion
All over the world, in rich and developing countries alike, 
a demographic shift towards an aging population is under-
way. How we handle aging populations will have major eco-
nomic and healthcare implications in the next few decades. 
Many infectious diseases inflict a disproportionate burden 
of disease in older adults and can contribute to the onset of 
frailty, but may be prevented or attenuated by vaccination. 
This implies that vaccination can serve as the third pillar 
of a strategy to support healthy aging, alongside healthy 
diet and exercise. However, the uptake of vaccination by 
the target population is generally low and must be substan-
tially improved if the potential of vaccines to reduce the 
morbidity, mortality, loss of quality of life and healthcare 
costs caused by VPDs is to be realized [12]. The available 
evidence indicates that vaccination coverage in older adults 
can be considerably improved, although there is a need for 
further research into the generalizability of particular inter-
ventions to improve coverage.
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Fig. 2  Components of successful vaccination programs. Healthcare 
systems are more than just government and business infrastructure: 
they comprise everyone involved in the process—politicians, health-
care providers and the general public. Each part of the polity engages 
in dialogue with the other parts, and it is plain that for the establish-
ment of successful vaccination programs—whether in children or in 
adults—all parts must be in general agreement [88, 89]. In addition, 
each part of the polity has specific roles in terms of delivery, dialogue 
and acceptance, as indicated by the labeled arrows. The media plays a 
significant, but different role. While not (in theory) directly involved 
in the process, it is the channel through which much of the dialogue is 
conducted, and can also act as an “amplifier”—for example, increas-
ing the visibility and impact of public concerns or hesitancy, or alter-
natively promoting vaccination by reporting on disease-related deaths 
or vaccine benefits
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